{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T01:02:34Z","timestamp":1787533354427,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>All non-sensitized Rhesus D (RhD)-negative pregnant women in Germany receive antenatal anti-D prophylaxis without knowledge of fetal RhD status. Non-invasive prenatal testing (NIPT) of cell-free fetal DNA in maternal plasma could avoid unnecessary anti-D administration. In this paper, we systematically reviewed the evidence on the benefit of NIPT for fetal RhD status in RhD-negative pregnant women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched several bibliographic databases, trial registries, and other sources (up to October 2019) for controlled intervention studies investigating NIPT for fetal RhD versus conventional anti-D prophylaxis. The focus was on the impact on fetal and maternal morbidity. We primarily considered direct evidence (from randomized controlled trials) or if unavailable, linked evidence (from diagnostic accuracy studies and from controlled intervention studies investigating the administration or withholding of anti-D prophylaxis). The results of diagnostic accuracy studies were pooled in bivariate meta-analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Neither direct evidence nor sufficient data for linked evidence were identified. Meta-analysis of data from about 60,000 participants showed high sensitivity (99.9%; 95% CI [99.5%; 100%] and specificity (99.2%; 95% CI [98.5%; 99.5%]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NIPT for fetal RhD status is equivalent to conventional serologic testing using the newborn\u2019s blood. Studies investigating patient-relevant outcomes are still lacking.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12884-020-2742-4","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T06:04:07Z","timestamp":1581055447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8815-4885","authenticated-orcid":false,"given":"Britta","family":"Runkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Bein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Sieben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Sow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Polus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"2742_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1054\/blre.1999.0123","volume":"14","author":"SJ Urbaniak","year":"2000","unstructured":"Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and newborn. Blood Rev. 2000;14:44\u201361.","journal-title":"Blood Rev"},{"key":"2742_CR2","doi-asserted-by":"crossref","unstructured":"Crowther CA, Middleton P. Anti-D administration after childbirth for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev. 1997;(2):CD000021.","DOI":"10.1002\/14651858.CD000021"},{"key":"2742_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1055\/s-0038-1642063","volume":"35","author":"JD Sperling","year":"2018","unstructured":"Sperling JD, Dahlke JD, Sutton D, Gonzales JM, Chauhan MD. Prevention of RhD alloimmunization: a comparison of four national guidelines. Am J Perinatol. 2018;35:110\u20139.","journal-title":"Am J Perinatol"},{"key":"2742_CR4","doi-asserted-by":"crossref","unstructured":"McBain RD, Crowther CA, Middleton P. Anti-D administration in pregnancy for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev. 2015;(9):CD000020","DOI":"10.1002\/14651858.CD000020.pub3"},{"key":"2742_CR5","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1111\/j.1537-2995.2008.01843.x","volume":"48","author":"SP M\u00fcller","year":"2008","unstructured":"M\u00fcller SP, Bartels I, Stein W, Emons G, Gutensohn K, K\u00f6hler M, et al. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible. Transfusion (Paris). 2008;48:2292\u2013301.","journal-title":"Transfusion (Paris)"},{"key":"2742_CR6","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJM199812103392402","volume":"339","author":"YM Lo","year":"1998","unstructured":"Lo YM, Hjelm NM, Fidler C, Sargent IL, Murphy MF, Chamberlain PF, et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med. 1998;339:1734\u20138.","journal-title":"N Engl J Med"},{"key":"2742_CR7","volume-title":"General methods: version 5.0","author":"Institute for Quality and Efficiency in Health Care","year":"2017","unstructured":"Institute for Quality and Efficiency in Health Care. General methods: version 5.0. 2017. https:\/\/www.iqwig.de\/download\/General-Methods_Version-5-0.pdf."},{"key":"2742_CR8","volume-title":"Non-invasive determination of the fetal rhesus factor to prevent maternal rhesus sensitization: report plan [German]","author":"Institute for Quality and Efficiency in Health Care","year":"2017","unstructured":"Institute for Quality and Efficiency in Health Care. Non-invasive determination of the fetal rhesus factor to prevent maternal rhesus sensitization: report plan [German]. 2017. https:\/\/www.iqwig.de\/download\/D16-01_Bestimmung-fetaler-Rhesusfaktor_Berichtsplan_V1-0.pdf. ."},{"key":"2742_CR9","unstructured":"Institute for Quality and Efficiency in Health Care. Non-invasive determination of the fetal rhesus factor to prevent maternal rhesus sensitization: final report [German]. 2018. https:\/\/www.iqwig.de\/download\/D16-01_Bestimmung-fetaler-Rhesusfaktor_Abschlussbericht_V1-0.pdf. Accessed 21 Feb 2019."},{"key":"2742_CR10","unstructured":"Institute for Quality and Efficiency in Health Care. Non-invasive determination of the fetal rhesus factor to prevent maternal rhesus sensitization: extract. 2018. https:\/\/www.iqwig.de\/download\/D16-01_Determination-of-fetal-rhesus-factor_Extract-of-final-report_V1-0.pdf. Accessed 21 Feb 2019."},{"key":"2742_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med"},{"key":"2742_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1017\/S0266462313000287","volume":"29","author":"T Merlin","year":"2013","unstructured":"Merlin T, Lehman S, Hiller JE, Ryan P. The \"linked evidence approach\" to assess medical tests: a critical analysis. Int J Technol Assess Health Care. 2013;29:343\u201350.","journal-title":"Int J Technol Assess Health Care"},{"key":"2742_CR13","unstructured":"Hausner E, Ebrahim S, Herrmann-Frank A, Janzen T, Kerekes MF, Pischedda M, et al. Study selection by means of a web-based trial selection DataBase (webTSDB). Cochrane Database Syst Rev. 2011:16\u20137."},{"key":"2742_CR14","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ."},{"key":"2742_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529\u201336.","journal-title":"Ann Intern Med"},{"key":"2742_CR16","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/(SICI)1521-4036(199912)41:8<901::AID-BIMJ901>3.0.CO;2-W","volume":"41","author":"J Hartung","year":"1999","unstructured":"Hartung J. An alternative method for meta-analysis. Biom J. 1999;41:901\u201316.","journal-title":"Biom J"},{"key":"2742_CR17","doi-asserted-by":"publisher","first-page":"i5789","DOI":"10.1136\/bmj.i5789","volume":"355","author":"M De Haas","year":"2016","unstructured":"De Haas M, Thurik FF, Van der Ploeg CP, Veldhuisen B, Hirschberg H, Soussan AA, et al. Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands. BMJ. 2016;355:i5789.","journal-title":"BMJ."},{"key":"2742_CR18","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/pd.4419","volume":"34","author":"FB Clausen","year":"2014","unstructured":"Clausen FB, Steffensen R, Christiansen M, Rudby M, Jakobsen MA, Jakobsen TR, et al. Routine noninvasive prenatal screening for fetal RHD in plasma of RhD-negative pregnant women: 2\u2009years of screening experience from Denmark. Prenat Diagn. 2014;34:1000\u20135.","journal-title":"Prenat Diagn"},{"key":"2742_CR19","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/aogs.13191","volume":"96","author":"K Haimila","year":"2017","unstructured":"Haimila K, Sulin K, Kuosmanen M, Sareneva I, Korhonen A, Natunen S, et al. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women: outcome of the first two years of a national program in Finland. Acta Obstet Gynecol Scand. 2017;96:1228\u201333.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2742_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/AOG.0b013e31825d33d9","volume":"120","author":"AT Wikman","year":"2012","unstructured":"Wikman AT, Tiblad E, Karlsson A, Olsson ML, Westgren M, Reilly M. Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol. 2012;120:227\u201334.","journal-title":"Obstet Gynecol"},{"key":"2742_CR21","doi-asserted-by":"publisher","first-page":"g5243","DOI":"10.1136\/bmj.g5243","volume":"349","author":"LS Chitty","year":"2014","unstructured":"Chitty LS, Finning K, Wade A, Soothill P, Martin B, Oxenford K, et al. Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation: population based cohort study. BMJ. 2014;349:g5243.","journal-title":"BMJ."},{"key":"2742_CR22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1136\/bmj.39518.463206.25","volume":"336","author":"K Finning","year":"2008","unstructured":"Finning K, Martin P, Summers J, Massey E, Poole G, Daniels G. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ. 2008;336:816\u20138.","journal-title":"BMJ."},{"key":"2742_CR23","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.cca.2011.11.004","volume":"413","author":"HC Macher","year":"2012","unstructured":"Macher HC, Noguerol P, Medrano-Campillo P, Garrido-Marquez MR, Rubio-Calvo A, Carmona-Gonzalez M, et al. Standardization non-invasive fetal RHD and SRY determination into clinical routine using a new multiplex RT-PCR assay for fetal cell-free DNA in pregnant women plasma: results in clinical benefits and cost saving. Clin Chim Acta. 2012;413:490\u20134.","journal-title":"Clin Chim Acta"},{"key":"2742_CR24","first-page":"757","volume":"49","author":"CA Hyland","year":"2017","unstructured":"Hyland CA, Millard GM, O\u2019Brien H, Schoeman EM. Non-invasive fetal RHD genotyping for RhD negative women stratified into RHD gene deletion or variant groups: comparative accuracy using two blood collection tube types. Pathology (Phila). 2017;49:757\u201364.","journal-title":"Pathology (Phila)"},{"key":"2742_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5694\/j.1326-5377.2009.tb02668.x","volume":"191","author":"CA Hyland","year":"2009","unstructured":"Hyland CA, Gardener GJ, Davies H, Ahvenainen M, Flower RL, Irwin D, et al. Evaluation of non-invasive prenatal RHD genotyping of the fetus. Med J Aust. 2009;191:21\u20135.","journal-title":"Med J Aust"},{"key":"2742_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000322959","volume":"29","author":"R Akolekar","year":"2011","unstructured":"Akolekar R, Finning K, Kuppusamy R, Daniels G, Nicolaides KH. Fetal RHD genotyping in maternal plasma at 11-13 weeks of gestation. Fetal Diagn Ther. 2011;29:301\u20136.","journal-title":"Fetal Diagn Ther"},{"key":"2742_CR27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1537-2995.2007.01533.x","volume":"48","author":"JM Minon","year":"2008","unstructured":"Minon JM, Gerard C, Senterre JM, Schaaps JP, Foidart JM. Routine fetal RHD genotyping with maternal plasma: a four-year experience in Belgium. Transfusion (Paris). 2008;48:373\u201381.","journal-title":"Transfusion (Paris)"},{"key":"2742_CR28","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1111\/1471-0528.13055","volume":"122","author":"PW Soothill","year":"2015","unstructured":"Soothill PW, Finning K, Latham T, Wreford-Bush T, Ford J, Daniels G. Use of cffDNA to avoid administration of anti-D to pregnant women when the fetus is RhD-negative: implementation in the NHS. BJOG. 2015;122:1682\u20136.","journal-title":"BJOG."},{"key":"2742_CR29","first-page":"101","volume":"16","author":"J Huchet","year":"1987","unstructured":"Huchet J, Dallemagne S, Huchet C, Brossard Y, Larsen M, Parnet-Mathieu F. Ante-partum administration of preventive treatment of Rh-D immunization in Rhesus-negative women: parallel evaluation of transplacental passage of fetal blood cells; results of a multicenter study carried out in the Paris region [French]. J Gynecol Obstet Biol Reprod (Paris). 1987;16:101\u201311.","journal-title":"J Gynecol Obstet Biol Reprod (Paris)"},{"key":"2742_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1365-3148.1995.tb00180.x","volume":"5","author":"D Lee","year":"1995","unstructured":"Lee D, Rawlinson VI. Multicentre trial of antepartum low-dose anti-D immunoglobulin. Transfus Med. 1995;5:15\u20139.","journal-title":"Transfus Med"},{"key":"2742_CR31","unstructured":"Pilgrim H, Lloyd-Jones M, Rees A. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation. Health Technol Assess. 2009;13:iii, ix-xi, 1\u2013103."},{"key":"2742_CR32","doi-asserted-by":"publisher","first-page":"e30711","DOI":"10.1371\/journal.pone.0030711","volume":"7","author":"RM Turner","year":"2012","unstructured":"Turner RM, Lloyd-Jones M, Anumba DO, Smith GC, Spiegelhalter DJ, Squires H, et al. Routine antenatal anti-D prophylaxis in women who are Rh(D) negative: meta-analyses adjusted for differences in study design and quality. PLoS One. 2012;7:e30711.","journal-title":"PLoS One"},{"key":"2742_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/1471-0528.14050","volume":"124","author":"FL Mackie","year":"2017","unstructured":"Mackie FL, Hemming K, Allen S, Morris RK, Kilby MD. The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis. BJOG. 2017;124:32\u201346.","journal-title":"BJOG."},{"key":"2742_CR34","volume-title":"High-throughput non-invasive prenatal testing for fetal RHD genotype","author":"National Institute for Health and Care Excellence","year":"2016","unstructured":"National Institute for Health and Care Excellence. High-throughput non-invasive prenatal testing for fetal RHD genotype. 2016. https:\/\/www.nice.org.uk\/guidance\/dg25\/resources\/highthroughput-noninvasive-prenatal-testing-for-fetal-rhd-genotype-1053691935685."},{"key":"2742_CR35","volume-title":"High-throughput, non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation","author":"CRD\/CHE Technology Assessment Group","year":"2016","unstructured":"CRD\/CHE Technology Assessment Group. High-throughput, non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation. 2016. https:\/\/www.nice.org.uk\/guidance\/dg25\/documents\/diagnostics-assessment-report."},{"key":"2742_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta22130","volume":"22","author":"P Saramago","year":"2018","unstructured":"Saramago P, Yang H, Llewellyn A, Walker R, Harden M, Palmer S, et al. High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation. Health Technol Assess. 2018;22:1\u2013172.","journal-title":"Health Technol Assess"},{"key":"2742_CR37","volume-title":"New blood test for pregnant women could help thousands avoid unnecessary treatment","author":"National Institute for Health and Care Excellence","year":"2016","unstructured":"National Institute for Health and Care Excellence. New blood test for pregnant women could help thousands avoid unnecessary treatment. 2016. https:\/\/www.nice.org.uk\/news\/article\/new-blood-test-for-pregnant-women-could-help-thousands-avoid-unnecessary-treatment."},{"key":"2742_CR38","volume-title":"High-throughput non-invasive prenatal testing for fetal RHD genotype: recommendations","author":"National Institute for Health and Care Excellence","year":"2016","unstructured":"National Institute for Health and Care Excellence. High-throughput non-invasive prenatal testing for fetal RHD genotype: recommendations. 2016. https:\/\/www.nice.org.uk\/guidance\/dg25\/chapter\/1-Recommendations. ."},{"key":"2742_CR39","volume-title":"D\u00e9termination pr\u00e9natale du g\u00e9notype RHD foetal \u00e0 partir du sang maternel: rapport d\u2019\u00e9valuation technologique","author":"Haute Autorit\u00e9 de Sant\u00e9","year":"2011","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. D\u00e9termination pr\u00e9natale du g\u00e9notype RHD foetal \u00e0 partir du sang maternel: rapport d\u2019\u00e9valuation technologique. 2011. https:\/\/www.has-sante.fr\/portail\/plugins\/ModuleXitiKLEE\/types\/FileDocument\/doXiti.jsp?id=c_1108581."},{"key":"2742_CR40","volume-title":"D\u00e9termination pr\u00e9natale du g\u00e9notype RHD foetal \u00e0 partir du sang maternel: avis sur les actes","author":"Haute Autorit\u00e9 de Sant\u00e9","year":"2011","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. D\u00e9termination pr\u00e9natale du g\u00e9notype RHD foetal \u00e0 partir du sang maternel: avis sur les actes. 2011. https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2011-10\/avis_genotypage_foetal.pdf."},{"key":"2742_CR41","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence; publication bias. J Clin Epidemiol. 2011;64:1277\u201382.","journal-title":"J Clin Epidemiol"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-020-2742-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12884-020-2742-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-020-2742-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T01:44:37Z","timestamp":1722390277000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-020-2742-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2742"],"URL":"https:\/\/doi.org\/10.1186\/s12884-020-2742-4","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"assertion":[{"value":"9 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the final version of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}